Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 combinations in advanced hepatocellular carcinoma
NCT06233994Not yet recruiting
- Sponsor
- Changsha Taihe Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of nilvanstomig in hepatocellular carcinoma (HCC) (2 arms), sponsored by Changsha Taihe Hospital. Primary endpoints: Objective Response Rate at 2 years and Progression-Free Survival at 2 years. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
nilvanstomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06233994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233994.